FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.

Related Keywords

Texas ,United States ,Houston ,Ashling Wahner ,Courtneyd Dinardo ,Linkedin ,Division Of Cancer Medicine ,Twitter ,Facebook ,University Of Texas Md Anderson Cancer Center ,Department Of Leukemia ,Onclive On Air ,Live On Air ,Cancer Medicine ,Cancer Center ,Apple Podcasts ,Google Podcasts ,Amazon Music ,Fda Approval Of Ivosidenib ,Patients With Relapsed Refractory Idh1 Mutant Myelodysplastic Syndromes ,Ag120c 001 Trial ,D ,Osce ,The University Of Texas Md Anderson Cancer Center ,Nct02074839 ,